(Q45030051)

English

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

0 references

colorectal carcinoma

1 reference

based on heuristic

inferred from title

medical oncology

1 reference

based on heuristic

inferred from title

Rocío García-Carbonero

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Santiago Ramon y Cajal

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

Pilar García-Alfonso

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Ramón Salazar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Jesús García-Foncillas

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Eva Musulén

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Artemio Payá

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Pedro Pérez-Segura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Samuel Navarro

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Spanish Society of Medical Oncology (SEOM)

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Spanish Society of Pathology (SEAP)

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

27 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Clinical and Translational Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

726-739

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22855150%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

https://scigraph.springernature.com/pub.10.1007/s12094-012-0856-5

0 references

New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

The DCC protein and prognosis in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Systematic review of microsatellite instability and colorectal cancer prognosis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Right- and left-sided colorectal cancers display distinct expression profiles and the anatomical stratification allows a high accuracy prediction of lymph node metastasis.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Molecular staging for survival prediction of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PTEN status in advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Immunohistochemical expression of EGFR in colorectal carcinoma correlates with high but not low level gene amplification, as demonstrated by CISH.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

EGFR and colon cancer: a clinical view.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Clinical significance of tumor suppressor PTEN in colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

A robust immunohistochemical assay for detecting PTEN expression in human tumors

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Current overview of the role of Akt in cancer studies via applied immunohistochemistry

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

SMAD4 as a Prognostic Marker in Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS12094-012-0856-5

21 January 2018

American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple Gene Expression Classifiers from Different Array Platforms Predict Poor Prognosis of Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colorectal Cancer OncoGuia: surgical pathology report guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stage II colon cancer prognosis prediction by tumor gene expression profiling

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hereditary colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/22855150

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45030051&oldid=1531883184"